Curated News
By: NewsRamp Editorial Staff
February 25, 2026
Anixa's CAR-T Pioneer to Keynote 2026 Retreat on Ovarian Cancer Therapy Trial
TLDR
- Anixa Biosciences gains visibility as its co-inventor presents at a key 2026 conference, potentially boosting investor interest in its novel CAR-T therapy for recurrent ovarian cancer.
- Anixa's lira-cel therapy uses CER-T technology, where FSH binds to FSHR on tumor cells, differing from antibody-based CAR-T, in a Phase 1 trial for ovarian cancer.
- This therapy offers hope to women with recurrent ovarian cancer who have exhausted other treatments, advancing personalized medicine and improving quality of life.
- Anixa's CAR-T technology, co-invented by a Duke professor, targets ovarian cancer with a unique approach, highlighting innovation in biotechnology and cancer research.
Impact - Why it Matters
This development matters because it highlights significant progress in treating recurrent ovarian cancer, a disease with limited options after multiple relapses. Anixa's CER-T technology represents a novel approach in immunotherapy that could offer new hope for patients who have exhausted standard therapies. The involvement of top institutions like Duke, Moffitt, and Cleveland Clinic underscores the scientific rigor and potential impact of this research. Advances in targeted cell therapies like this could pave the way for more effective, personalized cancer treatments, potentially improving survival rates and quality of life for those affected by aggressive cancers. It also showcases how biotechnology companies are leveraging academic partnerships to accelerate innovation from lab to clinic.
Summary
Anixa Biosciences, Inc. (NASDAQ: ANIX), a clinical-stage biotechnology company, has announced that Dr. Jose Conejo-Garcia, a key co-inventor of its CAR-T technology and a Professor at Duke University, will deliver a keynote presentation at the South Carolina Clinical & Translational Research Institute's 2026 Retreat focused on cell-based therapies. His presentation is expected to highlight the company's ongoing Phase 1 clinical trial for liraltagene autoleucel (lira-cel), an innovative FSHR-targeted CAR-T therapy for recurrent ovarian cancer. This therapy, first discovered at The Wistar Institute, represents a novel approach using chimeric endocrine receptor-T cell (CER-T) technology, which differentiates it from other cell therapies by utilizing the natural ligand FSH instead of an antibody fragment to bind to tumor cells.
The company's therapeutic portfolio is developed through strategic collaborations with leading research institutions. Lira-cel is being advanced in partnership with Moffitt Cancer Center, a world leader in cancer immunotherapy. Additionally, Anixa's vaccine portfolio, developed in collaboration with Cleveland Clinic, includes vaccines targeting breast cancer, ovarian cancer, and other intractable cancers like those in the lung, colon, and prostate. These vaccines aim to immunize against "retired" proteins expressed in certain cancers. This unique business model allows Anixa to leverage cutting-edge research from top institutions for commercialization, with partners like Cleveland Clinic entitled to royalties from related technologies.
This news was disseminated through BioMedWire (BMW), a specialized communications platform within the Dynamic Brand Portfolio of IBN, which provides extensive distribution services including wire solutions, editorial syndication, and social media outreach to enhance brand awareness in the biotechnology and life sciences sectors. For more details, readers can view the full press release via the provided link. To learn more about Anixa's initiatives, visit their official website. BioMedWire continues to serve as a convergence point for breaking news and actionable information in the biomedical field.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Anixa's CAR-T Pioneer to Keynote 2026 Retreat on Ovarian Cancer Therapy Trial
